Observational studyCancer medicine2025
Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatric drugs · 2026Review
- Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.Cancer medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlinatumomab has been approved for the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). This study aimed to investigate the association between leukemia burden and the efficacy of blinatumomab in real-world applications.
methodsA real-world study was conducted by enrolling patients aged 0-18 years who were diagnosed with CD19-positive B-ALL and treated with blinatumomab between January 2021 and May 2023 from 14 centers in China.
resultsA total of 304 patients were enrolled in this analysis. In the patients with > 5% blasts before blinatumomab (non-complete remission, NCR group), 75.9% achieved complete remission (CR) and 69.0% of the NCR patients achieved minimal residual disease (MRD) negativity. Among the patients with ≤ 5% blasts but multiparametric flow cytometry MRD (MFC MRD) positive (MRD+ group), 98.9% achieved MRD negativity. Of the MFC MRD negative patients (MRD- group), the quantitative polymerase chain reaction MRD (qPCR MRD) and next-generation sequencing MRD (NGS MRD) clearance rate was 60.0% (12/20) and 65.5% (19/29), respectively. Additionally, patients in the MRD- and MRD+ groups had significantly better outcomes than those in the NCR group, with 30-month overall survival (OS) rates of 95.3% (95% CI: 91.4%-99.3%), 91.2% (95% CI: 85.0%-97.8%), and 77.6% (95% CI: 67.4%-89.4%), respectively (p < 0.001), and 30-month event-free survival (EFS) rates of 93.9% (95% CI: 89.6%-98.3%), 90.8% (95% CI: 85.0%-97.1%), and 56.7% (95% CI: 41.0%-78.6%), respectively (p < 0.001). In this study, 41.4% of patients experienced grade ≥ 3 adverse events (AEs), with hematological toxicity being the most common (33.2%). The severe adverse events, such as cytokine release syndrome (CRS) and neurotoxicity, occurred at a low rate, particularly grade ≥ 3, at 3.6% and 2.6%, respectively.
conclusionsOverall, these results indicate that blinatumomab is effective and well tolerated. Patients with a lower leukemia burden before blinatumomab administration tend to have better OS and EFS with fewer AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.